Drugs / MRX-4
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03033329 | Oct 2016 → Mar 2018 | — | MicuRx | Completed | No outcome recorded |
| Phase 1 | NCT03033342 | Aug 2016 → Feb 2017 | — | MicuRx | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MRX-4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03033342 ↗ |
| Modality | Small molecule | “a new oxazolidinone antibiotic” NCT03033329 ↗ |
| Route | Intravenous | “Intravenous single escalating doses of MRX-4” NCT03033329 ↗ |